Modifiers of Huntingtin and Alpha-synuclein Toxicity
Modifiers of Huntingtin and Alpha-synuclein Toxicity
批准号:
7163529
负责人:
PAUL J MUCHOWSKI
金额:
$37.89万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-01-01 至 2008-12-31
关键词:
AffectAlzheimer&aposs DiseaseAmyloidAmyloid beta-ProteinAnimal ModelBiochemicalBiologicalBiological AssayBradykinesiaCategoriesCell DeathCell SurvivalCellsCharacteristicsCytoplasmic InclusionDementiaDiseaseFluorescence MicroscopyGene-ModifiedGenesGeneticGenomeGoalsHumanHuntington DiseaseInborn Genetic DiseasesInclusion BodiesInformation ResourcesInheritedInvoluntary MovementsLeadLewy BodiesMeasuresMediatingModelingMolecularMolecular GeneticsMolecular TargetMonitorMuscle RigidityNatureNerve DegenerationNeurodegenerative DisordersNeuronal DysfunctionNeuronsOrganismOrthologous GeneParkinson DiseasePathway interactionsPersonalityPoint MutationPropertyProteinsResearch PersonnelRest TremorRoleSNCA geneScreening procedureStressStructureTechniquesTestingToxic effectYeast Model SystemYeastsalpha synucleinamyloid formationbaseearly onsethuman Huntingtin proteinlipid metabolismpolyglutamineprogramsprotein aggregationprotein foldingresearch studyresponsesynucleintherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Huntington's disease (HD) is an autosomal dominant inherited disorder characterized by involuntary movements, personality changes and dementia, and is caused by an expansion of a CAG/polyglutamine repeat in the IT-15 gene. A major neuropathological hallmark in HD is the occurrence of intranuclear and cytoplasmic inclusion bodies that contain huntingtin (the protein encoded by IT-15). Cytoplasmic inclusion bodies (Lewy bodies) are also a prominent nature of Parkinson's disease (PD), a neurodegenerative disorder characterized by muscle rigidity, bradykinesia, resting tremor and postural instability. Lewy bodies are composed primarily of the protein alpha-synuclein, and two point mutations in the alpha-synuclein gene cause early-onset, inherited forms of Parkinson's disease. Alpha-synuclein and huntingtin aggregate into ordered fibrillar structures with properties characteristic of amyloid. The 'amyloid hypothesis', developed originally to describe the role of beta-amyloid in Alzheimer's Disease (AD), suggests that the aggregation of proteins into an ordered fibrillar structure is causally related to aberrant protein interactions that culminate in neuronal dysfunction and cell death (Hardy and Selkoe, 2002). The precise roles of protein aggregation, amyloid formation and inclusion bodies in neurodegeneration remain controversial, and it is not yet clear if common molecular mechanisms underlie HD and Parkinson's disease.
We have used yeast as a model eukaryotic organism to test the hypothesis that the downstream targets and molecular mechanisms by which huntingtin and ot-synuclein mediate toxicity are unique. Using a genome-wide screening approach in yeast we isolated 52 genes that modify huntingtin toxicity, and 86 genes that modify alpha-synuclein toxicity. 30% of genes that affect huntingtin toxicity are enriched in the functionally related categories of protein folding and cell stress, while 29% of genes that modify alpha-synuclein toxicity are involved in vesicular transport and lipid metabolism. Our preliminary results indicate surprisingly that the genes and cellular pathways that modulate huntingtin and alpha-synuclein toxicity in yeast are completely divergent. Nearly half of the genes we isolated are annotated as having one or more human ortholog, suggesting we may have discovered in yeast conserved cell-biological response pathways to huntingtin and alpha-synuclein that are relevant to HD and Parkinson's disease. Using the resources and information that we have generated, we now wish to advance our understanding of the neurodegeneration that occurs in HD and PD by applying molecular genetic and biochemical techniques to validate (or invalidate) the genetic modifiers we have identified. Our long-term goal is to use the information we gain in these studies to test hypotheses in animal models of HD and Parkinson's disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Microglia and the Kynurenine Pathway in Huntington's Disease
-
批准号:8053283
-
项目类别:
-
资助金额:$37.26万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
The Role of Microglia and the Kynurenine Pathway in Huntington's Disease
-
批准号:8417949
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Microglial Kynurenine Pathway and Selective Neuronal Vulnerability
-
批准号:7468582
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
The Role of Microglia and the Kynurenine Pathway in Huntington's Disease
-
批准号:7799078
-
项目类别:
-
资助金额:$37.77万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
The Role of Microglia and the Kynurenine Pathway in Huntington's Disease
-
批准号:7467434
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
The Role of Microglia and the Kynurenine Pathway in Huntington's Disease
-
批准号:7875707
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
The Role of Microglia and the Kynurenine Pathway in Huntington's Disease
-
批准号:7572825
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2008
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Elucidation of the structures and biological activities of huntingtin oligomers
-
批准号:7578853
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2006
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Elucidation of the structures and biological activities of huntingtin oligomers
-
批准号:7214058
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2006
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Elucidation of the structures and biological activities of huntingtin oligomers
-
批准号:7774994
-
项目类别:
-
资助金额:$41.53万
-
财政年份:2006
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Elucidation of the structures and biological activities of huntingtin oligomers
-
批准号:7076778
-
项目类别:
-
资助金额:$43.2万
-
财政年份:2006
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Elucidation of the structures and biological activities of huntingtin oligomers
-
批准号:7350895
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2006
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Modifiers of Huntingtin and Alpha-synuclein Toxicity
-
批准号:6705353
-
项目类别:
-
资助金额:$31.17万
-
财政年份:2004
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Modifiers of Huntingtin and Alpha-synuclein Toxicity
-
批准号:7001315
-
项目类别:
-
资助金额:$39.02万
-
财政年份:2004
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Modifiers of Huntingtin and Alpha-synuclein Toxicity
-
批准号:7340755
-
项目类别:
-
资助金额:$37.89万
-
财政年份:2004
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Modifiers of Huntingtin and Alpha-synuclein Toxicity
-
批准号:6835151
-
项目类别:
-
资助金额:$31.17万
-
财政年份:2004
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Microglial Kynurenine Pathway and Selective Neuronal Vulnerability
-
批准号:8377817
-
项目类别:
-
资助金额:$26.06万
-
财政年份:--
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Microglial Kynurenine Pathway and Selective Neuronal Vulnerability
-
批准号:8067041
-
项目类别:
-
资助金额:$40.57万
-
财政年份:--
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Microglial Kynurenine Pathway and Selective Neuronal Vulnerability
-
批准号:7844883
-
项目类别:
-
资助金额:$38.84万
-
财政年份:--
-
负责人:PAUL J MUCHOWSKI
-
依托单位:
Microglial Kynurenine Pathway and Selective Neuronal Vulnerability
-
批准号:8286956
-
项目类别:
-
资助金额:$52.51万
-
财政年份:--
-
负责人:PAUL J MUCHOWSKI
-
依托单位: